Halozyme Therapeutics

Update in progress

HALO (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Halozyme Therapeutics, Inc. is a biopharmaceutical company that develops proprietary enzymes and related devices based on recombinant human hyaluronidase (rHuPH20) to enable subcutaneous administration of injectable biologics and other therapies. It markets Hylenex recombinant and XYOSTED, and collaborates with partners including Roche, Takeda, Pfizer, and AbbVie. Founded 1998, San Diego.

Company score

Sentiment: 0.46; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.02; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.23; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.07; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.09; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.27; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive